	US 12,311,058 B2
	Single protein-encapsulated pharmaceutics for enhancing therapeutic effects
Changjun Yu, Pasadena, CA (US)
Assigned to SUNSTATE BIOSCIENCES, LLC, Pasadena, CA (US)
Filed by Sunstate Biosciences, LLC, Pasadena, CA (US)
Filed on Mar. 30, 2023, as Appl. No. 18/128,828.
Application 18/128,828 is a division of application No. 16/601,333, filed on Oct. 14, 2019, granted, now 11,696,957.
Claims priority of provisional application 62/746,964, filed on Oct. 17, 2018.
Prior Publication US 2024/0016948 A1, Jan. 18, 2024
Int. Cl. A61K 31/136 (2006.01); A61K 9/50 (2006.01); A61K 31/337 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/519 (2006.01); A61K 31/704 (2006.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01)

CPC A61K 9/5052 (2013.01) [A61K 31/136 (2013.01); A61K 31/337 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/519 (2013.01); A61K 31/704 (2013.01); A61K 47/643 (2017.08); A61K 47/6809 (2017.08); A61K 47/6835 (2017.08); A61P 35/00 (2018.01)]

19 Claims

1. A composition, comprising a single protein selected from the group consisting of an albumin, a globulin, and a fibrinogen having a plurality of molecules of an anticancer agent tightly bound therein,

wherein the anticancer agent is selected from the group consisting of actinomycin D, SN-38, and docetaxel, and

wherein the protein is not present in the form of a nanoparticle.